What was the impact of the Spanish COPD guidelines (GesEPOC) and how can they be improved?;¿Qué ha supuesto la Guía Española de la EPOC (GesEPOC) y cómo puede mejorar?

Archivos de Bronconeumologia

Volumn 52, Issue 1, 2016, Pages 1-2

  Miravitlles, Marc ^a,b  

^a HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^b INSTITUTO DE SALUD CARLOS III   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

CHRONIC OBSTRUCTIVE LUNG DISEASE; EDITORIAL; PRACTICE GUIDELINE; SPAIN; HUMAN; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; STANDARDS; TOTAL QUALITY MANAGEMENT; ARTICLE; ASTHMA CHRONIC OBSTRUCTIVE LUNG DISEASE OVERLAP SYNDROME; CONFLICT OF INTEREST; DISEASE CONTROL; DISEASE SEVERITY; EMPHYSEMA; OBSTRUCTIVE AIRWAY DISEASE; PUBLICATION;

HUMANS; PRACTICE GUIDELINES AS TOPIC; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; QUALITY IMPROVEMENT; SPAIN;

EID: 84961216728     PISSN: 03002896     EISSN: 15792129     Source Type: Journal    
DOI: 10.1016/j.arbr.2015.04.029     Document Type: Article

References (12)

1. Miravitlles M., Soler-Cataluña J.J., Calle M., Molina J., Almagro P., Quintano J.A., et al. Spanish Guideline for COPD (GesEPOC). Update 2014. Arch Bronconeumol 2014, 50(Suppl 1):S1-S16.
2. Han M.K., Agusti A., Calverley P.M., Celli B.R., Criner G., Curtis J.L., et al. Chronic obstructive pulmonary disease phenotypes: The future of COPD. Am J Respir Crit Care Med 2010, 182:598-604.
3. Miravitlles M., Calle M., Soler-Cataluña J.J. Clinical phenotypes of COPD. Identification, definition and implications for guidelines. Arch Bronconeumol 2012, 48:86-98.
4. Vestbo J., Hurd S.S., Agusti A.G., Jones P.W., Vogelmeier C., Anzueto A., et al. Global strategy for the diagnosis, management and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit Care Med 2013, 187:347-365.
5. Zysman M., Patout M., Miravitlles M., van der Molen T., Lokke A., Hausen T., et al. COPD and perception of the new GOLD document in Europe. Workshop from the Société de pneumologie de langue française (SPLF). Rev Mal Respir 2014, 31:499-510. [Article in French].
6. Koblizek V., CHlumsky J., Zindr V., Neumannova K., Zatloukal J., Zak J., et al. Chronic Obstructive Pulmonary Disease: Official diagnosis and treatment guidelines of the Czech Pneumonogical and Phthisiological Society: A novel phenotypic approach to COPD with patient oriented care. Pap Med Fac Univ Palacky Olomouc Czech Repub 2013, 157:189-201.
7. Kankaanranta H., Harju T., Kilpeläinen M., Mazur W., Lehto J.T., Katajisto M., et al. Diagnosis and pharmacotherapy of stable chronic obstructive pulmonary disease: The Finnish Guidelines. Guidelines of the Finnish Medical Society Duodecim and the Finnish respiratory Society. Basic Clin Pharmacol Toxicol. 2015, 116:291-307.
8. Golpe R., Sanjuán López P., Cano Jiménez E., Castro-Añón O., Pérez de Llano L.A. Distribution of clinical phenotypes in patients with chronic obstructive pulmonary disease caused by biomass and tobacco smoke. Arch Bronconeumol 2014, 50:318-324.
9. GINA-GOLD Diagnosis of disease of chronic airflow limitation: Asthma, COPD and asthma-COPD overlap syndrome (ACOS) [consultado 5 Ene 2015]. Disponible en: . http://www.goldcopd.org/asthma-copd-overlap.html.
10. Barrecheguren M., Esquinas C., Miravitlles M. The asthma COPD overlap syndrome (ACOS). Opportunities and challenges. Curr Opin Pulm Med 2015, 21:74-79.
11. Soler-Cataluña J.J., Alcazar B., Miravitlles M. The concept of control of COPD in clinical practice. Int J Chron Obst Pulm Dis 2015, 10:1-9.
12. Agustí A. The path to personalised medicine in COPD. Thorax 2014, 69:857-864.